Literature DB >> 25827967

Risk factors for spinal cord ischemia after endovascular repair of thoracoabdominal aortic aneurysms.

Theodosios Bisdas1, Giuseppe Panuccio2, Masayuki Sugimoto2, Giovanni Torsello2, Martin Austermann2.   

Abstract

OBJECTIVE: The introduction of fenestrated and multibranched endografting transformed the treatment paradigm of patients with thoracoabdominal aortic aneurysms (TAAAs). However, despite the minimally invasive character of the procedure, spinal cord ischemia (SCI) remains a devastating complication. The aim of this study was to address the SCI rates after endovascular TAAA repair and to analyze potential risk factors leading to this complication.
METHODS: A consecutive cohort of patients with nonruptured TAAAs treated by means of fenestrated and multibranched endografting between January 2010 and September 2014 was analyzed. Neurologic examination was routinely performed by an independent neurologist before operation and at discharge. The main outcome measure was the onset of SCI (paraplegia or paraparesis). Secondary outcomes were neurologic complications associated with cerebrospinal fluid drainage (CSFD) and 30-day mortality. Finally, a multivariate regression analysis identified risk factors for SCI.
RESULTS: A consecutive 142 patients with TAAAs (Crawford type II, n = 54 [38%]; type III, n = 76 [54%]; type IV, n = 12 [8%]) were included in this study. The majority of patients (n = 129 [91%]) were treated for an atherosclerotic aneurysm, whereas 13 patients (9%) were treated for a postdissection aneurysm. The mean maximal aortic diameter was 65 ± 13 mm. SCI developed in 23 patients (16%; paraplegia in 12 [8%] and paraparesis in 11 [8%]). Of these 23 patients, 10 patients (43%) showed the neurologic deficit directly after the procedure, 11 patients (48%) in the first 24 hours, and 2 patients (9%) after 24 hours. There was an improvement of the neurologic status in the majority of patients, with only three patients (2%) showing irreversible paraplegia at discharge. There was no difference in the 30-day mortality between patients with and without SCI (no SCI, n = 3 [3%] vs SCI, n = 1 [4%]; P = .511). Prophylactic use of CSFD before the procedure was performed in 64 patients (45%), and among them, 4 patients (6%) developed a CSFD-associated complication. No clinical benefit for patients receiving prophylactic placement of CSFD was found (P = .498). The multivariate analysis revealed the percentage of thoracic aortic coverage as the only significant risk factor for SCI (odds ratio, 1.03; 95% confidence interval, 1.01-1.05; P = .001).
CONCLUSIONS: The SCI rate after endovascular repair of TAAA was 16%, with 8% of those patients suffering from paraplegia. Prophylactic use of CSFD could not reduce the SCI rate and was associated with 6% adverse events. The percentage of thoracic aortic coverage was the most powerful determinant of SCI in these series.
Copyright © 2015 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25827967     DOI: 10.1016/j.jvs.2015.01.044

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  16 in total

1.  Rates of Spinal Cord Infarction After Repair of Aortic Aneurysm or Dissection.

Authors:  Gino Gialdini; Neal S Parikh; Abhinaba Chatterjee; Michael P Lerario; Hooman Kamel; Darren B Schneider; Babak B Navi; Santosh B Murthy; Costantino Iadecola; Alexander E Merkler
Journal:  Stroke       Date:  2017-06-27       Impact factor: 7.914

Review 2.  Endovascular repair for thoracoabdominal aortic aneurysms: current status and future challenges.

Authors:  Emanuel R Tenorio; Marina F Dias-Neto; Guilherme Baumgardt Barbosa Lima; Anthony L Estrera; Gustavo S Oderich
Journal:  Ann Cardiothorac Surg       Date:  2021-11

Review 3.  Spinal cord injury after thoracic endovascular aortic aneurysm repair.

Authors:  Hamdy Awad; Mohamed Ehab Ramadan; Hosam F El Sayed; Daniel A Tolpin; Esmerina Tili; Charles D Collard
Journal:  Can J Anaesth       Date:  2017-10-10       Impact factor: 5.063

4.  New Preoperative Spinal Cord Ischemia Risk Stratification Model for Patients Undergoing Thoracic Endovascular Aortic Repair.

Authors:  Albeir Y Mousa; Ramez Morcos; Mike Broce; Mark C Bates; Ali F AbuRahma
Journal:  Vasc Endovascular Surg       Date:  2020-06-04       Impact factor: 1.089

Review 5.  Narrative review on endovascular techniques for left subclavian artery revascularization during thoracic endovascular aortic repair and risk factors for postoperative stroke.

Authors:  Mario D'Oria; Kevin Mani; Randall DeMartino; Martin Czerny; Konstantinos P Donas; Anders Wanhainen; Sandro Lepidi
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-05-10

6.  Macrophage Migration Inhibitory Factor Predicts Outcome in Complex Aortic Surgery.

Authors:  Alexander Gombert; Christian Stoppe; Ann Christina Foldenauer; Tobias Schuerholz; Lukas Martin; Johannes Kalder; Gereon Schälte; Gernot Marx; Michael Jacobs; Jochen Grommes
Journal:  Int J Mol Sci       Date:  2017-11-09       Impact factor: 5.923

7.  Perioperative cerebrospinal fluid drainage for the prevention of spinal ischemia after endovascular aortic repair.

Authors:  M Wortmann; D Böckler; P Geisbüsch
Journal:  Gefasschirurgie       Date:  2017-05-16

8.  Paraplegia after coronary artery bypass surgery: An uncommon complication in a patient with history of thoracic endovascular aortic repair.

Authors:  Aurélien Vallée; Stephan Haulon; Alexandre Azmoun; Julien Guihaire
Journal:  J Vasc Surg Cases Innov Tech       Date:  2018-12-04

9.  Aortic remodeling in Type B aortic dissection after thoracic endovascular aortic repair with an aortic extender cuff implantation.

Authors:  Honggang Zhang; Tong Qiao
Journal:  Clin Interv Aging       Date:  2018-11-15       Impact factor: 4.458

10.  Paraplegia prevention in aortic aneurysm repair by thoracoabdominal staging with 'minimally invasive staged segmental artery coil embolisation' (MIS²ACE): trial protocol for a randomised controlled multicentre trial.

Authors:  David Petroff; Martin Czerny; Tilo Kölbel; Germano Melissano; Lars Lonn; Josephina Haunschild; Konstantin von Aspern; Petra Neuhaus; Johann Pelz; David Mark Epstein; Nuria Romo-Avilés; Katja Piotrowski; Christian D Etz
Journal:  BMJ Open       Date:  2019-03-04       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.